Market-View-Feature-Image

View on market: Stay Cautious, be with quality business:

Asian stocks were steady Tuesday while Treasury yields and the dollar trimmed gains as traders weighed inflation concerns and the prospect of a quicker tapering of central bank stimulus. Shares rose in Japan and South Korea but slipped in Australia. U.S. futures were little changed after the S&P 500 and Nasdaq 100 ended flat. The Singapore-traded SGX Nifty added 0.24% to 18,187, as of 8:05a.m. U.S. President Joe Biden and Chinese leader Xi Jinping began a face-to-face virtual summit. Any signs of improving bilateral ties could help sentiment, but the effect may be short lived given wider concerns in markets over inflation and the fallout of Xi’s “common prosperity” drive to tackle inequality.

Economic Calendar:

  • INR: M3 Money Supply on 17th November, 2021.
  • INR: Bank Loan & Deposit Growth on 19th November, 2021.
  • USD: Core Retail Sales (MoM) (Oct) on 16th November, 2021.
  • USD: Building Permits (Oct) on 17th November, 2021.

Brokerage Radar:

JEFFERIES ON ASHOK LEYLAND: Maintain buy at the price of Rs 152 for the target price of Rs 175. Truck Demand Is Recovering Fast, Expect A Big Upturn ahead. Truck Market Share Has Dropped 10 ppt Since FY18. Rationale For Sale Of e- Mobility Service Biz To Promoter Entity Is Also Unclear.

CS ON ULTRATECH: Maintain outperform at the price of Rs 8038 for the target price of Rs 9250. House Construction Activity Pick-up can Drive positive Surprise On Cement Demand. This Driver Can Turn Around & Drive Demand For Cement Ahead Of Expectations.

International Markets:

U.S & Europe

Particulars 15th Nov Chg Chg(%)
Nasdaq 15,853.85 -7.11 -0.04
Dow 36,087.45 -12.86 -0.04
FTSE 7,351.86 3.95 0.05
CAC 7,128.63 37.23 0.53
DAX 16,148.64 54.57 0.34
Dow Fut.* 36,037.00 28.00 0.08

Asian markets:

Particulars 16th Nov Chg Chg(%)
SGX Nifty 18,187.00 48.00 0.26
Nikkei 29,836.74 59.94 0.20
Straits Times 3,242.75 2.17 0.07
Hang Seng 25,557.54 166.63 0.66
Shanghai 3,543.78 10.48 0.30

ADR Watch:

Particulars 15th Nov Chg Chg(%)
Dr Reddy 65.38 0.32 0.49
HDFC Bank 70.98 -0.77 -1.07
ICICI Bank 20.52 -0.14 -0.68
Infosys 23.63 -0.07 -0.30
Tata Motor 33.57 0.00 0.00
Wipro 9.05 -0.10 -1.09

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR 74.48 0.06
Brent 82.83   0.90
Gold 1870.90 0.23
Silver 25.255 0.60

FIIs & DII

Particulars 15th Nov 12th Nov
FIIs 424.74 511.10
DIIs 1524.67 851.41

News Update:

Macrotech Developers: The company launched its Rs 4,000 crore qualified institutional placement on Monday. It plans to issue about 3.4 crore shares. The floor price is set at Rs 1,184.70 per which is at a discount of 7.8% to last close of Rs 1,284.60. Proceeds to be used for capital expenditure including acquisition of land, land development rights or development rights, deleveraging and general corporate purposes.

The Phoenix Mills: The company and Canada Pension Plan Investment Board have entered into an agreement to develop an office-led mixed-use asset in Lower Parel, Mumbai. CPP Investments will invest up to Rs 1,350 crore in tranches, for an ultimate equity stake of 49% in Plutocrat Commercial Real Estate Private Limited, the entity that will own the asset. The target completion date for the development is 2026.

Escorts: Board to meet on November 18 to consider fundraising options. Further Escorts Agri Machinery will be increasing the prices of its tractors effective November 21. The company cited steady rise in commodity prices as the reason behind price hike. The increase in prices would vary across models and variants.

Cipla: The company has been selected in the S&P Dow Jones Sustainability Index for the Emerging Markets for 2021.

SBI Cards and Payment Services: Approved allotment of 5,000 unsecured NCDs of face value of Rs 10 lakh each aggregating to Rs 500 crore on private placement basis. The coupon rate is set at 5.75% per annum.

Reddy’s Laboratories: The pharma major, among the handful of Indian drug companies licensed to make a new covid-19 pill developed by Merck, has said it was open to making a similar pill from Pfizer, thought to be even more effective. The new drugs, which unlike vaccines can be used to treat patients once they contract coronavirus infection, are expected to be a huge market.

Bharti Airtel: Has partnered with US-based Mavenir for open radio access network (Open RAN)-based fifth generation or 5G field trials in the mmWave and mid band at Chandigarh tri-city.

Vodafone Idea: The debt-ridden telecom operator is evaluating the option of converting interest dues arising out of deferment of statutory payments into equity, a senior company official said. The company is also in talks with banks and investors for raising funds and part of the proceeds is likely to be utilised towards meeting obligations related to debt maturing this fiscal.

Ashok Leyland: Hinduja group flagship Ashok Leyland is working on hydrogen-powered commercial vehicles, with a team is currently engaged in developing them. For the time being, the company will stick to its ₹750 crore capital expenditure for this financial year.

Coforge Ltd: The company, formerly NIIT Technologies and which is promoted by PE major Barings Private Equity Asia, is likely to soon file papers with the US Securities Exchange Commission for an initial public offer via American Depository Receipts route.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL